Paratek announces inclusion of oral NUZYRA in China’s NRDL

Paratek Pharmaceuticals announced that China’s National Healthcare Security Administration has added the oral formulation of NUZYRA to the country’s National Reimbursement Drug List for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Earlier this year, NHSA added the intravenous formulation of NUZYRA to the NRDL for the treatment of CABP and ABSSSI. NUZYRA was granted approval by the U.S. Food and Drug Administration in October 2018 and Paratek launched the product in the United States in February 2019. Paratek’s partner in China, Zai Lab, received approval of both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration of China for the treatment of CABP and ABSSSI in December 2021.